anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a randomized, prospective, double-blinded study evaluating the efficacy of Fortiva Porcine Dermis versus Strattice Reconstructive Tissue Matrix in 120 patients with large complex abdominal wall ventral hernias undergoing single stage repair. The patient will be blinded to treatment as well as an independent qualified evaluator to confirm evidence of reoccurrence. This post-market study compares two FDA cleared biologic hernia materials. Fortiva™ porcine dermis, processed by RTI Surgical, Inc., a non-cross linked porcine dermis will be compared to Strattice™ Reconstructive Tissue Matrix by Life Cell, a non-cross linked porcine dermis for reinforcement during the single stage open reconstruction of abdominal wall defects. The primary outcome will be hernia recurrence at 1 year. Outcomes will be evaluated at 6 weeks, 3 months, 6 months and 12 months and 24 months.
This was a cross-sectional study conducted in Bangkok and surrounding provinces. Approximately 1500 participants were enrolled. Study staff interviewed participants on basic demographic data, health status, physical activities, food frequency and 24-hour recall. Anthropometry (body weight, height, hip and waist circumference) and physical assessment (blood pressure)were measured. Ten milliliters of venous blood was drawn by venipuncture after a 12 h overnight fast for determination of fasting plasma glucose (FPG) and blood lipid concentrations (total cholesterol, triglyceride, and HDL-cholesterol). FPG was measured by the enzymatic colorimetric method with glucose oxidase.21 Total cholesterol was determined by the cholesterol oxidase method and serum triglycerides concentration was determined by standardized enzymatic procedures using glycerol phosphate oxidase assay.22, 23 HDL- cholesterol was measured by enzymatic assays.24 LDL cholesterol was calculated according to the method of Friedwald et al.25 All samples were analyzed when internal quality control met the acceptable criteria. Intra-and inter-assay CVs were 2.01% and 3.01% for FPG, 1.87% and 4.24% for total cholesterol, 0.93% and 11.6% for triacylglycerols, and 0.99% and 1.49% for HDL cholesterol, respectively.
Patients in this arm will receive standard anaesthesia as per our bariatric anaesthesia protocol. They will also receive preoperative ultrasound guided bilateral single shot erector spinae plane blocks at the level of the 8th transverse process.
Under general anesthesia, patients are positioned in the left lateral decubitus position and undergo endoscopic examination of the esophagus and stomach. The surgery utilizes a single-channel gastroscope (EG29-i10, Pentax, Japan, or GIF-H290T, Olympus, Japan) and a high-frequency generator (VIO300D, Erbe, Germany). A transparent cap (D-201, Olympus, Japan) is attached to the gastroscope to improve visualization and aid in manipulating the flap valve. The DualKnife (Olympus, Japan) is selected for dissection due to its maneuverability in a retroflexed fashion. For patients with esophageal strictures obstructing scope passage, esophageal dilation is performed using Savary-Gilliard dilators (Cook Medical, USA) just before ARMV.
Drug-induced liver injury (DILI), especially acetaminophen overdose, is the leading cause of acute liver failure. Pregnane X receptor (PXR) is a nuclear receptor and the master regulator of drug metabolism. Aberrant activation of PXR plays a pathogenic role in the acetaminophen hepatotoxicity. Here, we aimed to examine the S-nitrosylation of PXR (SNO-PXR) in response to acetaminophen. We found that PXR was S-nitrosylated in hepatocytes and the mouse livers after exposure to acetaminophen or S-nitrosoglutathione (GSNO). Mass spectrometry and site-directed mutagenesis identified the cysteine 307 as the primary residue for S-nitrosylation (SNO) modification. In hepatocytes, SNO suppressed both agonist-induced (rifampicin and SR12813) and constitutively active PXR (VP-PXR, a human PXR fused to the minimal transactivator domain of the herpes virus transcription factor VP16) activations. Furthermore, in acetaminophen-overdosed mouse livers, PXR protein was decreased at the centrilobular regions overlapping with increased SNO. In PXR-/- mice, replenishing the livers with the SNO-deficient PXR significantly aggravated hepatic necrosis, increased HMGB1 release, and exacerbated liver injury and inflammation. Particularly, we demonstrated that S-nitrosoglutathione reductase (GSNOR) inhibitor N6022 promoted hepatoprotection by increasing the levels of SNO-PXR. In conclusion, PXR is posttranslationally modified by SNO in hepatocytes in response to acetaminophen. This modification mitigated the acetaminophen-induced PXR hyperactivity. It may serve as a target for therapeutical intervention.
Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems utilize a synthetic, random copolymer polypeptide containing about 8 to about 40 amino acid residues that includes the overlapping five and six amino acid residue sequences -Gly-R1-Gly-R2-Gly-(i) wherein R1 and R2 are amino acid residues selected from Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr with the provision that R1 and R2 are not both Gly; and -Gly-Ala-Gly-Gly-Ala-Gly-. (ii)  The polypeptide contains at least 50 mole percent Gly residues. The diagnostic method and system are particularly useful for assaying for the stage of mononucleois disease, and the presence of nasopharynegeal carcinoma. Assaying for anti-Epstein-Barr virus nuclear antigen antibodies is carried out by mixing a body sample with the synthetic polypeptide, allowing antibodies in the sample to immunoreact with the polypeptide to form an immunoreactant and determining the immunoreactant.  In another embodiment, the synthetic polypeptide is fixed to a solid phase and a solid phase immunoreactant obtained from immunoreacting with antibodies in the sample is mixed with anti-heavy chain antibodies to form a second immunoreactant which is determined. The anti-antibodies can be anti-IgG or anti-IgM, and the anti-antibodies can be linked to an indicating means such as an enzyme.
BACKGROUND: Appropriate preoperative management of patients with chronic moderate to severe shoulder pain who are candidates for surgery owing to rotator cuff disease or glenohumeral osteoarthritis may improve surgery and patient outcomes, but published evidence in this regard is scarce. Therefore, the availability of recommendations on preoperative interventions based on expert consensus may serve as guidance.
METHODS: A Delphi study was conducted to develop a preoperative management algorithm based on a national expert consensus. A Delphi questionnaire was developed by a scientific committee following a systematic review of the relevant literature published during the past 10 years using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) criteria. It consisted of 48 statements divided into 5 blocks (block I, assessment and diagnosis of preoperative pain; block II, preoperative function and psychosocial aspects; block III, therapeutic objectives; block IV, treatment; and block V, follow-up and referral), and 28 experienced shoulder surgeons from across the country were invited to answer.
RESULTS: All participants responded to the Delphi questionnaire in the first round, and 25 responded in the second round (89.3% of those invited). Overall, 46 of 49 final statements reached a consensus, on the basis of which a final preoperative management algorithm was defined by the scientific committee. First, surgeons should assess shoulder pain intensity and characteristics, shoulder functionality, and psychosocial aspects using specific validated questionnaires. Preoperative therapeutic objectives should include shoulder pain control, depression and/or nocturnal sleep improvement, opioid consumption adjustment, and substance abuse cessation. Postoperative objectives regarding the degree of shoulder pain reduction or improvement in functionality and/or quality of life should be established in agreement with the patient. Treatment of preoperative chronic moderate to severe shoulder pain should comprise nonpharmacologic as well as pharmacologic interventions. Follow-up of the shoulder pain levels, treatment adherence, and mental health status of these patients may be carried out by the surgical team (surgeon and anesthesiologist) together with the primary care team. Patients with very intense shoulder pain levels may be referred to a pain unit following specific protocols.
CONCLUSION: A preoperative management algorithm for patients with chronic moderate to severe shoulder pain who are candidates for surgery owing to rotator cuff disease or glenohumeral osteoarthritis was defined based on a national expert consensus. Main points include comprehensive patient management starting with an objective assessment of shoulder pain and function, as well as quality of life; establishment of preoperative and postoperative therapeutic targets; prescription of individualized therapeutic interventions; and multidisciplinary patient follow-up. Implementation of these recommendations into clinical practice may result in better preoperative shoulder pain management and more successful surgical outcomes and patient satisfaction.
PURPOSE:To prepare a cosmetic having improved dispersibility and miscibility of an inorganic pigment in an oily raw material, and improved applicability, safety, stability and feeling, etc., to the skin, by compounding an inorganic pigment surface-treated with a specific N-mono-long-chain acyl basic amino acid. CONSTITUTION:The surface of an inorganic pigment is treated with an N-mono- long-chain-acyl basic amino acid containing one 8-22C aliphatic acyl group in the molecule, e.g. N<alpha>- or N<epsilon>-long-chain-acyl lysine, N<alpha>- or N<delta>-long-chain-acyl ornithine, N<alpha>- or N<gamma>-long-chain-acyl-alpha,gamma-diaminobutyric acid, etc. The treated inorganic pigment is compounded to a cosmetic to improve the above characteristics of the cosmetic. A cosmetic having uniform quality, free from stickiness, giving smooth feeling to the skin, spreadable easily on the skin, having durable cosmetic effect, forming little peroxides, and having various other advantages can be prepared by this process. The amount of the amino acid is preferably 0.05-5wt% based on the inorganic pigment.
FIELD: immunochemistry. SUBSTANCE: method involves separation of pig peripheral blood in gradient ficoll-verographin at density 1.078 g/cm. The isolated lymphocyte fraction is treated with phytohemagglutinin, supernatant is cultured, cell-free supernatant is taken off, concentrated by ultrafiltration on diaphragm filters PM-10 and separated using Sephadex G-100. Two active fractions of molecular mass 60-70 and 20-30 kDa were obtained. These fractions effect on motility of phagocytic cells and show accelerating effect of wound healing processes. EFFECT: simplified method.
PURPOSE:A fat transfusion agent containing dietetically necessary fatty acids in good balance, having antithromobotic action, comprising docosahexaenoic acid, its ester, or their mixture, a vegetable oil, an emulsifying agent water. CONSTITUTION:5-20w/v% docosahexaenoic acid, or its ester (e.g., docosahexaenoic acid triglyceride, or its ethyl ester), or their mixture is blended with 1-19w/v% vegetable oil, 1-2w/v% emulsifying agent, and the rest of water, to give a fat transfusion solution agent. In human serum or cells, a large amount of >=20C fatty acids such as eicosapentaenoic acid, docosahexaenoic acid, etc. exist, existing fat transfusion solution agent comprising a vegetable oil as a lipoid component is dietetically unsatisfactory. The fat transfusion solution agent of this invention contains fatty acids in good balance, which are required with respect to the science of nutrition. It is also useful as an antithromobotic agent and an antiarteriosclerotic agent.
PROBLEM TO BE SOLVED: To obtain a irritation-preventing agent for suppressing an irritation derived from irritating substances, useful for protecting of a skin, hair and nails by containing a specific compound having remarkable water retention as an effective component. SOLUTION: This agent contains trehalose or its derivative as an effective component. Sulfated trehalose or acylated trehalose is esp. suitable as trehalose derivatives. The objective cosmetic for preventing irritation contains preferably 0.001-20wt.%, esp. preferably 0.05-10wt.% of the irritation-preventing agent. Creams, cosmetic water, hair tonics, shampoos, nail colors, foundations, bath bubbles, etc., are exemplified as the cosmetic for preventing irritation.
Health care for the homeless population is a complex challenge and represents a significant gap in care, particularly for those at the end of life. Hospice care may be desired but is rarely an option for people without residences, social support, and payment sources. Social model hospice is a unique paradigm of care delivery that offers a viable solution to make hospice and palliative care possible for this population. In this historical report from interviews with early organizers, prior and current leadership (n = 6), the evolution of The INN Between in Salt Lake City, Utah, is described. In 2010, The INN Between was conceptualized as a nonprofit community effort addressing this need to provide an alternative to people dying unsheltered. After 5 years of planning, it opened in 2015 and has grown to become a comprehensive community resource for homeless medically frail and terminally ill individuals. Recommendations for establishing social model hospices are made: key strategies include identifying stakeholders dedicated to alleviating end-of-life homelessness needs, doing a formal needs assessment to identify community resource deficits, and forming mentoring relationships with established programs. Social model hospice is a viable way of meeting the end-of-life needs of many communities' most vulnerable residents.
Epidemiological studies have shown the association of genetic variants with risks of occupational and environmentally induced cancers, including bladder (BC). The current review summarizes the effects of variants in genes encoding phase I and II enzymes in well-designed studies to highlight their contribution to BC susceptibility and prognosis. Polymorphisms in genes codifying drug-metabolizing proteins are of particular interest because of their involvement in the metabolism of exogenous genotoxic compounds, such as tobacco and agrochemicals. The prognosis between muscle-invasive and non-muscle-invasive diseases is very different, and it is difficult to predict which will progress worse. Web of Science, PubMed, and Medline were searched to identify studies published between January 1, 2010, and February 2023. We included 73 eligible studies, more than 300 polymorphisms, and 46 genes/loci. The most studied candidate genes/loci of phase I metabolism were CYP1B1, CYP1A1, CYP1A2, CYP3A4, CYP2D6, CYP2A6, CYP3E1, and ALDH2, and those in phase II were GSTM1, GSTT1, NAT2, GSTP1, GSTA1, GSTO1, and UGT1A1. We used the 46 genes to construct a network of proteins and to evaluate their biological functions based on the Reactome and KEGG databases. Lastly, we assessed their expression in different tissues, including normal bladder and BC samples. The drug-metabolizing pathway plays a relevant role in BC, and our review discusses a list of genes that could provide clues for further exploration of susceptibility and prognostic biomarkers.
BACKGROUND: The intravesical instillation of the paclitaxel-hyaluronan conjugate ONCOFID-P-B™ in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladder carcinoma in situ (CIS; NCT04798703 phase I study), induced 75 and 40% of complete response (CR) after 12 weeks of intensive phase and 12 months of maintenance phase, respectively. The aim of this study was to provide a detailed description of the tumor microenvironment (TME) of ONCOFID-P-B™-treated BCG-unresponsive bladder CIS patients enrolled in the NCT04798703 phase I study, in order to identify predictive biomarkers of response.
METHODS: The composition and spatial interactions of tumor-infiltrating immune cells and the expression of the most relevant hyaluronic acid (HA) receptors on cancer cells, were analyzed in biopsies from the 20 patients enrolled in the NCT04798703 phase I study collected before starting ONCOFID-P-B™ therapy (baseline), and after the intensive and the maintenance phases. Clinical data were correlated with cell densities, cell distribution and cell interactions. Associations between immune populations or HA receptors expression and outcome were analyzed using univariate Cox regression and log-rank analysis.
RESULTS: In baseline biopsies, patients achieving CR after the intensive phase had a lower density of intra-tumoral CD8+ cytotoxic T lymphocytes (CTL), but also fewer interactions between CTL and macrophages or T-regulatory cells, as compared to non-responders (NR). NR expressed higher levels of the HA receptors CD44v6, ICAM-1 and RHAMM. The intra-tumoral macrophage density was positively correlated with the expression of the pro-metastatic and aggressive variant CD44v6, and the combined score of intra-tumoral macrophage density and CD44v6 expression had an AUC of 0.85 (95% CI 0.68-1.00) for patient response prediction.
CONCLUSIONS: The clinical response to ONCOFID-P-B™ in bladder CIS likely relies on several components of the TME, and the combined evaluation of intra-tumoral macrophages density and CD44v6 expression is a potentially new predictive biomarker for patient response. Overall, our data allow to advance a potential rationale for combinatorial treatments targeting the immune infiltrate such as immune checkpoint inhibitors, to make bladder CIS more responsive to ONCOFID-P-B™ treatment.
To provide: a method for improvement of intestinal environment; and a model of intestinal environment.SOLUTION: There is provided an intestinal ammonia concentration reduction composition which includes digestion-resistant dextrin and inulin. The mass ratio between the digestion-resistant dextrin and the inulin in the composition may be, for example, 1:99 to 99:1. The composition may be used for making intestinal environment better. There is also provided a stool culturing medium containing urea. The ratio of the contained urea to the medium by mass may be 0.1 mass% or more. The medium may be used for culturing intestinal bacteria.SELECTED DRAWING: Figure 4
BACKGROUND: Intraoperative fluid management is a crucial aspect of cancer surgery, including colorectal surgery and pancreatoduodenectomy. The study tests if intraoperative multimodal monitoring reduces postoperative morbidity and duration of hospitalisation in patients undergoing major abdominal surgery treated by the same anaesthetic protocols with epidural analgesia.
PATIENTS AND METHODS: A prospective study was conducted in 2 parallel groups. High-risk surgical patients undergoing major abdominal surgery were randomly selected in the control group (CG), where standard monitoring was applied (44 patients), and the protocol group (PG), where cerebral oxygenation and extended hemodynamic monitoring were used with the protocol for intraoperative interventions (44 patients).
RESULTS: There were no differences in the median length of hospital stay, CG 9 days (interquartile range [IQR] 8 days), PG 9 (5.5), p = 0.851. There was no difference in postoperative renal of cardiac impairment. Procalcitonin was significantly higher (highest postoperative value in the first 3 days) in CG, 0.75 mcg/L (IQR 3.19 mcg/L), than in PG, 0.3 mcg/L (0.88 mcg/L), p = 0.001. PG patients received a larger volume of intraoperative fluid; median intraoperative fluid balance +1300 ml (IQR 1063 ml) than CG; +375 ml (IQR 438 ml), p < 0.001.
CONCLUSIONS: There were significant differences in intraoperative fluid management and vasopressor use. The median postoperative value of procalcitonin was significantly higher in CG, suggesting differences in immune response to tissue trauma in different intraoperative fluid status, but there was no difference in postoperative morbidity or hospital stay.
The invention relates to a detoxifying and tissue regeneration promoting powder for treating skin trauma. Aiming at the existing fact that the medicines have certain stimulation sensitivity to special individuals. The product has dark color, and the color difference on the skin after being smeared affects the beauty and mental state. The invention screens and dries the mentholum, the asarum, the alum, the pearl powder, the hemsleya amabilis, the serissa serissoides and the subprostrate sophora. Grinding, sieving, adding nitrofurazone powder, mixing and blending to obtain the product. The stimulation and the sensitive side effect are reduced to the minimum, the treatment range is expanded, and the treatment function is deepened. The medicinal powder can be directly shaken and skimmed on the affected part by exposure therapy, and is beneficial for scabbing. It has inhibiting and killing effects on Staphylococcus, Diplococcus gonorrhoeae, Pseudomonas aeruginosa, Escherichia coli, and Trichomonas.
BACKGROUND: Synthesizing current evidence on interventions to improve survival outcomes in preterm infants is crucial for informing programs and policies. The objective of this study is to investigate the impact of topical emollient oil application on the weight of preterm infants.
METHODS: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted. To identify relevant studies, comprehensive searches were conducted across multiple databases, including PubMed, Cochrane, Scopus, Clinical trials, ProQuest Central, Epistemonikos, and gray literature sources. The inclusion criteria were based on the PICO (Population, Intervention, Comparison, and Outcomes) format. Study quality was assessed using the Cochrane risk of bias tool for randomized trials (RoB 2.0). Data analysis was performed using StataCrop MP V.17 software, which included evaluating heterogeneity, conducting subgroup analysis, sensitivity analysis, and meta-regression. The findings were reported in accordance with the PRISMA checklist, and the review was registered with PROSPERO (CRD42023413770).
RESULTS: Out of the initial pool of 2734 articles, a total of 18 studies involving 1454 preterm neonates were included in the final analysis. Fourteen of these studies provided data that contributed to the calculation of the pooled difference in mean weight gain in preterm neonates. The random effects meta-analysis revealed a significant pooled difference in mean weight gain of 52.15 grams (95% CI: 45.96, 58.35), albeit with high heterogeneity (I2 > 93.24%, p 0.000). Subgroup analyses were conducted, revealing that preterm infants who received massages three times daily with either sunflower oil or coconut oil exhibited greater mean differences in weight gain. Meta-regression analysis indicated that the type of emollient oil, duration of therapy, and frequency of application significantly contributed to the observed heterogeneity. A sensitivity analysis was performed, excluding two outlier studies, resulting in a pooled mean weight difference of 78.57grams (95% CI: 52.46, 104.68). Among the nine studies that reported adverse events, only two mentioned occurrences of rash and accidental slippage in the intervention groups.
CONCLUSION: The available evidence suggests that the application of topical emollient oil in preterm neonates is likely to be effective in promoting weight gain, with a moderate-to-high level of certainty. Based on these findings, it is recommended that local policymakers and health planners prioritize the routine use of emollient oils in newborn care for preterm infants. By incorporating emollient oils into standard care protocols, healthcare providers can provide additional support to promote optimal growth and development in preterm infants.